6 registrations that name riboflavin as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 6 registrations
Status
Phase
3US sites across 3 states
1
2 to 4
5 to 19
20 or more
All 6 registrations
RecruitingNCT07841470
Corneal Crosslinking for Treatment of Progressive Keratoconus or Corneal Ectasia
Phase 2 and 3
Price Vision Group
About 500 people
Started Oct 1, 2025
In plain words A Phase 2 and 3 study of riboflavin in people 10 to 90, run by Price Vision Group. It plans to enroll about 500 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 10 to 90. Conditions: Keratoconus; Corneal Ectasia.
Diagnosis of keratoconus or corneal ectasia
Provision of written informed consent
The exclusion criteria are on the listing.
What it tests, as registered
Riboflavin 0.1% ophthalmic solution and pulsed light; Riboflavin 0.1% ophthalmic solution and non-pulsed light
Registered summary
This randomized study compares 2 variations of corneal crosslinking for treatment of keratoconus or corneal ectasia.
Where, as registered
1 US site in 1 state.
RecruitingNCT07629557
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
Phase 4
Glaukos Corporation
About 15 people
Started May 11, 2026
In plain words A Phase 4 study of riboflavin in people 13 and older, run by Glaukos Corporation. It plans to enroll about 15 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 13 and older. Conditions: Keratoconus.
Provide written informed consent
Willing and able to comply with study instructions and follow-up visits
Diagnosis of keratoconus in each eye
The exclusion criteria are on the listing.
What it tests, as registered
Riboflavin Ophthalmic Solutions; UV-A Irradiation System
Registered summary
Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.
Where, as registered
1 US site in 1 state.
RecruitingNCT07093463
Colon-delivered Riboflavin and Gut Microbiota Composition
No phase
dsm-firmenich Switzerland AG
About 90 people
Started Jul 18, 2025
In plain words A study of riboflavin in people 50 to 70, run by dsm-firmenich Switzerland AG. It plans to enroll about 90 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 50 to 70; healthy volunteers accepted. Conditions: Microbiome Dysbiosis; Gut Health.
Individuals providing written informed consent for participation in the study and data processing
Female and males between 50 and 70 years of age
For females only: Menopausal as marked by at least 1 year since the last menstrual bleeding
Individuals with a BMI between 18.5 - 29.9 Kg/m2
7 more inclusion criteria and the exclusion criteria are on the listing.
Recent studies suggest B-vitamins such as riboflavin to possess prebiotic-like effects. However, there is still a lack of understanding of the exact host health benefits vs. conventional systemically available vitamin forms. The present study explores the benefit of colon-delivered vitamin B2 vs. conventional vitamin B2 in comparison to placebo in an aging population on gut microbiota and metabolic activity as well as gut health.
Where, as registered
No US site; Germany (1).
Not yet recruitingNCT04584125
A Randomized Clinical Trial of Ex Vivo Corneal Cross-Linking of Donor Keratoplasty Tissue for Keratoconus Used for Keratoplasty in Keratoconus Patients
No phase
Joseph B. Ciolino, MD
About 216 people
Starts Jan 1, 2027 (estimated)
In plain words A study of riboflavin in people 18 to 50, run by Joseph B. Ciolino, MD. It plans to enroll about 216 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 50. Conditions: Keratoconus.
Willing and able to provide written informed consent.
Willing and able to comply with study assessments for the full duration of the study.
Age ≥18 years but ≤50 years
History of keratoconus (without a previous transplant) requiring keratoplasty
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light; Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light
Registered summary
This randomized clinical trial will assess corneal astigmatism and visual outcomes in participants who have undergone corneal transplantation for keratoconus with ex vivo cross-linked donor corneal tissue versus participants who have undergone corneal transplantation for keratoconus with non-cross-linked donor corneas. Crosslinking is a procedure that stabilizes the biomechanical properties of the cornea; as a result, the cornea stiffens. It has been shown that this procedure stabilizes the cornea of patients with keratoconus or corneal ectasias. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT04731727
Treating Corneal Thinning Conditions With CCL Vario Riboflavin (CXL)
Early phase 1
Kent Wellish MD
About 600 people
Starts Jun 30, 2021 (estimated)
In plain words An early phase 1 study of riboflavin in people 12 and older, run by Kent Wellish MD. It plans to enroll about 600 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 12 and older. Conditions: Keratoconus, Unstable.
Presence of central or inferior corneal steepening
Axial topography consistent with keratoconus, post-surgical ectasia, or pellucid marginal degeneration
Presence of one or more findings associated with keratoconus or pellucid marginal degeneration, such as:
Fleischer ring
17 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Riboflavin
Registered summary
Study is testing the efficacy of treating corneal thinning conditions with Vitamin B2 (Riboflavin) and the application on UV Light.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07664657
To Assess Dose Proportionality and Pharmacokinetic Linearity of Saninova Tablets in Healthy Participants Under Fasting Conditions
No phase
Sichuan Credit Pharmaceutical Co., Ltd.
About 32 people
Starts Jun 2026 (estimated)
In plain words A study of riboflavin in people 18 to 45, run by Sichuan Credit Pharmaceutical Co., Ltd.. It plans to enroll about 32 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45; healthy volunteers accepted. Conditions: Bioavailability and Pharmacokinetics.
Participation is truly voluntarily.
Healthy adult, human Participants between 18 to 45 years of age (both inclusive) and weighing at least 50 kgs.
Having a Body Mass Index (BMI) between 18.50 and 30.00 Kg/m2 (both inclusive) calculated as weight in kg / height in m2.
Have normal clinically findings as judged by investigators during screening within 28 days prior to administration of first dose of study drug, medical history and examination, laboratory evaluations, 12-lead ECG recordings, chest X-ray…
10 more inclusion criteria and the exclusion criteria are on the listing.
An open-label, randomized, single dose study to assess dose proportionality and pharmacokinetic linearity in healthy participants under fasting condition.